News Article,Video
Maple Grove Medical Device Company Pioneers New Treatment For Prostate Cancer
June 18, 2020
CCX Media visited Francis Medical, Wednesday, June 17, 2020 for exclusive interviews with CEO and President, Mike Kujak, and Founder and CTO, Michael Hoey.
Their two-minute video includes an explanation of our revolutionary water vapor therapy, as well as plans for the future, including our VAPOR 1 clinical study.
Recent Posts
Francis Medical Receives FDA 510(k) Clearance for Use of the Vanquish® Water Vapor System for Prostate Tissue Ablation in Patients with Intermediate Risk Prostate Cancer
MINNEAPOLIS (Dec. 2, 2025) – Francis Medical, Inc.,a privately-held medical device company developing the breakthrough Vanquish® Water Vapor Ablation System
Press Release: Francis Medical Announces Completion of Enrollment in the VAPOR 2 Pivotal Study for Vanquish Prostate Cancer Treatment
February 25, 2025: Francis Medical completes enrollment in the company's VAPOR 2 Pivotal Study for Vanquish Prostate Cancer Treatment
Press Release: Francis Medical Announces Close of Record $80 Million Series C Equity Financing
January 8, 2025: Francis Medical raises record $80M in Series C to fund its VAPOR 2 study and U.S. launch of Vanquish, its proprietary prostate cancer treatment
Federal law (USA) restricts this device to sale by or on the order of a physician.
Refer to the device User Manual for a list of contraindications, warnings, and cautions.
Training: Do not operate the Vanquish System without completing Francis Medical-provided physician training. Untrained operation of the device may lead to improper use. Improper use can result in patient injury or equipment malfunction.